Compare Eli Lilly And Co (LLY) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs MINISO Group Holding Ltd — how do they compare? Eli Lilly And Co trades at $1,179.71 (market cap $1.02T), while MINISO Group Holding Ltd trades at $12.61 (market cap $3.87B). The key difference: Eli Lilly And Co is far larger — about 263.6× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (5.21%). Which is the better fit depends on your goals.
| LLY | MNSO | |
|---|---|---|
Market Cap | $1.02T | $3.87B |
Sector | Health | Technology |
52-Week High | $1.24K | $26.63 |
52-Week Low | $625.65 | $11.30 |
Enterprise Value | $1.06T | $4.54B |
Dividend Yield | 0.6% | 5.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,175.15, down 0.33% on the day, with a bullish technical signal and strong fundamental momentum. Revenue surged to $65.18B in 2025, with net income reaching $20.64B, and the company has beaten earnings estimates for three consecutive quarters. Recent news includes a lawsuit from Novo Nordisk over weight-loss drug advertising, but analyst sentiment remains overwhelmingly positive with a $1,380 consensus price target.
Outlook is supported by robust earnings growth and high profitability margins, but risks include competitive pressures and elevated valuation multiples. The stock's current price is near key resistance at $1,174, with institutional buying activity indicating continued confidence in Lilly's growth trajectory in the pharmaceutical sector.
MNSO trades at $12.79, up 0.31% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating EPS estimates with $0.591 versus $0.238 expected, and announced a HK$2 billion share repurchase program on June 29, 2026 (PRNewsWire). Revenue grew to $21.44 billion in 2025, with a net income margin of 8.98% and a P/E ratio of 13.02, indicating reasonable valuation.
The outlook is positive with projected revenue growth to $22.7 billion in 2026 and net profit doubling to $2.0 billion. However, risks include margin compression from rising expenses and mixed earnings history with two recent misses. Analyst consensus is 75% buy, but competitive pressures in retail remain a concern for sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
